6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation
Phase 2
6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation is one of 21 therapeutic programs targeting Malaria. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
479 competitors in Malaria
#DrugCompanyPhaseTrials
1Biltricide
BayerPreclinical
Stelara
Johnson & JohnsonPreclinical
6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation
SSerum Institute of India Pvt. Ltd.
Phase 2
Hydroxychloroquine Sulfate
NovartisPreclinical
Iron
WWatson Pharmaceuticals
Preclinical
IV LBH589
NovartisPreclinical
Mefloquine Plus Artesunate
Medicines for Malaria VenturePreclinical
IV Ceftriaxone
RRESnTEC, Institute of Research
Preclinical
RTS,S/AS01E
GSKPreclinical
Malarone
Medicines for Malaria VenturePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]